Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PRe-ART-2T

Financiado

Cerrado

Predictive REagent Antibody Replacement Technology stage 2 Translation

PRe-ART-2T will translate FET-OPEN project PRe-ART (Predictive Reagent Antibody Replacement Technology) from laboratory proof-of-concept to investment readiness. We retain Pre-ART?s original aim to disrupt the reagent antibody mar... ver más

31/05/2025

Líder desconocido

800K€

Presupuesto del proyecto: 800K€

Líder del proyecto Líder desconocido

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-03-17

HORIZON-EIC-2021-TRANSITIONOPEN-01: EIC Transition Open 2021 Scope:The EIC Transition Open aims at funding innovation activities that go beyond the experimental...

I+D

Cerrada hace 3 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 38 meses Fecha Inicio: 2022-03-17
Fecha Fin: 2025-05-31

Líder del proyecto Líder desconocido

Presupuesto del proyecto 800K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto PRe-ART-2T will translate FET-OPEN project PRe-ART (Predictive Reagent Antibody Replacement Technology) from laboratory proof-of-concept to investment readiness. We retain Pre-ART?s original aim to disrupt the reagent antibody market, which after forty years plus, is still based on monoclonal antibodies (mAbs) to detect biomolecules, when 50% of all commercial reagent mAbs have been shown to not function correctly. Pre-ART has successfully delivered a foundational platform technology to TRL3. Pre-ART-2T will develop the technology to TRL6, so empowering our aim to disrupt the reagent antibody market by replacing low-quality, commercial animal-derived reagent mAbs with high-performing synthetic alternatives, created by combining modules from our encyclopaedia of experimentally pre-selected amino acid-binding motifs. Multidisciplinarity is key to the current experimental success of PRe-ART. By combining collective expertise in biochemistry, computational protein design and protein engineering, we have created a virtuous circle wherein biochemical & structural data (UZH) inform our novel computational mutagenic predictions (UBT), that inform synthesis of highly-specified gene libraries (Aston), whose protein products are analysed though novel high-throughput screens (UZH). Key hits are analysed biochemically and structurally (UZH) and resulting data inform the next cycle. As the cycle reiterates, greater specificity ensues. We have thus created many new and extremely stable amino acid-binding motifs that we have also combined in a modular manner to successfully bind predicted peptide targets. The project has also resulted in novel modelling (ATLIGATOR), mutagenic (ParaMAX randomization) and screening procedures. In Pre-ART-T2 we will complete our suite of dArmRPs for natural and modified amino acids and further study their modularity by creating prototypes for four commercially-relevant targets. At the end of the PRE-ART-2T, we expect to seek investment of ~E20 M.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores